Video
Author(s):
OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.
OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
2 Commerce Drive
Cranbury, NJ 08512